FRESENIUS KABI USA LLC

Lobbying for FRESENIUS KABI USA LLC

Filing 3rd Quarter - Amendment

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Nov 25, 2025

Expenses

$340,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Illinois

Official filing document

Government bodies contacted 7

Commerce, Dept of (DOC)
Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)
SENATE
U.S. Trade Representative (USTR)
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 16

S 1954
Biosimilar Red Tape Elimination Act
HR 5526
Biosimilar Red Tape Elimination Act
S 1414
Expedited Access to Biosimilars Act
S 2276
ETHIC Act
HR 3269
ETHIC Act
S 1041
Affordable Prescriptions for Patients Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 43
Skinny Labels, Big Savings Act
S 1097
Interagency Patent Coordination and Improvement Act of 2025
HR 4570
Interagency Patent Coordination and Improvement Act of 2025
HR 4317
PBM Reform Act of 2025
HR 2214
DRUG Act
S 1553
PREVAIL Act
HR 3160
PREVAIL Act
S 2305
Biosimilar Red Tape Elimination Act
S 2658
Medication Affordability and Patent Integrity Act

Lobbying activity 6

Trade (domestic/foreign)

Drug Shortages Domestic Manufacturing Tariffs

Medicare/Medicaid

Drug Shortages and Medicaid ERISA Fiduciary Duty IRA Reform

Health Issues

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act S. 1414/H.R._: Expedited Access to Biosimilars Act S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 1041: Affordable Prescriptions for Patients Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 43: Skinny Labels, Big Savings Act S. 1097/H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 HR 4317: PBM Reform Act of 2025 HR 2214: DRUG Act S. 1553/H.R. 3160: PREVAIL Act S. 2305: Biosimilar Red Tape Elimination Act S. 2658: Medication Affordability and Patient Integrity Act ERISA Fiduciary Duty PTAB Discretionary Denials IRA Reform Human Factor Studies Interchangeability Biosimilar User Fee Act (BsUFA) Drug Shortages Domestic Manufacturing

Manufacturing

Domestic Manufacturing

Budget/Appropriations

Domestic Manufacturing Tariffs

PTAB Discretionary Denials

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.